Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Emiltatug ledadotin shows promising antitumor activity in various cancers, with manageable safety, highlighting its potential ...

An expert discusses how long-term follow-up data from the COMMANDS trial demonstrated sustained superiority of luspatercept ...

An expert discusses how the EPO-PRETAR trial results showed no significant difference in transfusion dependence between early ...

The ARANOTE trial (NCT04736199) represents a significant step forward in the treatment landscape for patients with metastatic hormone-sensitive prostate cancer (mHSPC). The study aimed to explore the ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...

During a live event, Tony Philip, MD, and participants discussed molecular profiling and active surveillance for desmoid ...

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed ...

The FDA prioritizes TAR-200 for treating high-risk bladder cancer, showcasing promising phase 2b study results and innovative ...

Researchers explore glioblastoma's genetic complexity using innovative spatial profiling, aiming to enhance treatment ...

George Mulligan, PhD, previews the FDA's ODAC meeting discussing the application of belantamab mafodotin-based combinations for the treatment of multiple myeloma.

During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in ...